Neoantigen Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
상품코드:1538521
리서치사:Lucintel
발행일:2024년 07월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신생항원 암백신 동향 및 전망
세계 신생항원 암백신 시장은 2024년부터 2030년까지 연평균 22.4%의 성장률로 2030년까지 약 9,030만 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 환자 맞춤형 치료를 위한 맞춤형 의료의 활용 확대, 전 세계 암 발병률 증가, 면역요법 및 맞춤형 의료의 지속적인 발전입니다. 세계 신생항원 암백신 시장의 미래는 흑색종, 뇌종양, 소화관, 폐암 시장에서의 기회로 인해 유망할 것으로 예상됩니다.
부문별 신생항원 암백신
이 조사에는 세계 신생항원 암백신의 제품별, 투여 경로별, 세포별, 용도별, 지역별 예측이 포함되어 있습니다.
신생항원 암백신 시장 인사이트
Lucintel은 예측 기간 동안 맞춤형 신생항원이 높은 성장세를 보일 것으로 예상하고 있습니다.
이 시장 중 폐는 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
북미는 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
자주 묻는 질문
Q1. 시장 규모는?
A1. 세계 신생항원 암백신 시장은 2030년까지 약 9,030만 달러에 달할 것으로 예상됩니다.
Q2. 시장 성장 예측은?
A2. 세계 신생항원 암백신 시장은 2024년부터 2030년까지 연평균 22.4%의 성장률을 기록할 것으로 예상됩니다.
Q3. 시장 성장에 영향을 미치는 주요 촉진요인은?
A3. 이 시장의 주요 촉진요인은 환자 맞춤형 치료를 위한 맞춤형 의료의 활용 확대, 전 세계 암 발병률 증가, 면역요법 및 맞춤형 의료의 지속적인 발전입니다.
Q4. 시장의 주요 부문은?
A4. 신생항원 암백신 시장의 미래는 흑색종, 뇌종양, 소화관, 폐암 시장에서의 기회로 인해 유망한 것으로 보입니다.
Q5. 시장의 주요 기업은?
A5. 신생항원 암백신의 주요 기업은 다음과 같습니다.
Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody
Q6. 향후 가장 큰 시장 부문은?
A6. Lucintel은 예측 기간 동안 맞춤형 신생항원이 높은 성장세를 보일 것으로 예상하고 있습니다.
Q7. 시장에서 향후 5년간 가장 큰 시장이 될 것으로 예상되는 지역은?
A7. 예측 기간 동안 북미가 가장 높은 성장을 보일 것으로 예상됩니다.
Q8. 보고서 사용자 정의가 가능합니까?
A8. 예, Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.
목차
제1장 주요 요약
제2장 세계의 신생항원 암백신 시장 : 시장 역학
소개, 배경, 분류
공급망
업계 성장 촉진요인과 과제
제3장 2018년부터 2030년까지 시장 동향과 예측 분석
거시경제 동향(2018-2023년)과 예측(2024-2030년)
세계의 신생항원 암백신 시장 동향(2018-2023년)과 예측(2024-2030년)
제품별 세계의 신생항원 암백신 시장
맞춤형 신생항원 백신
오프 더 쉘 신생항원 백신
투여 경로별 세계의 신생항원 암백신 시장
정맥내
근육내
경피
기타
세포별 세계의 신생항원 암백신 시장
자가이식
동종이계
용도별 세계의 신생항원 암백신 시장
악성 흑색종
뇌종양
위장
폐
기타
제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석
지역별 세계의 신생항원 암백신 시장
북미의 신생항원 암백신 시장
유럽의 신생항원 암백신 시장
아시아태평양의 신생항원 암백신 시장
기타 지역의 신생항원 암백신 시장
제5장 경쟁 분석
제품 포트폴리오 분석
업무 통합
Porter's Five Forces 분석
제6장 성장 기회와 전략 분석
성장 기회 분석
제품별 세계의 신생항원 암백신 시장 성장 기회
투여 경로별 세계의 신생항원 암백신 시장 성장 기회
세포별 세계의 신생항원 암백신 시장 성장 기회
용도별 세계 신생항원 암백신 시장 성장 기회
지역별 세계의 신생항원 암백신 시장 성장 기회
세계의 신생항원 암백신 시장 최신 동향
전략 분석
신제품 개발
세계의 신생항원 암백신 시장 생산능력 확대
세계의 신생항원 암백신 시장 합병, 인수, 합작투자
인증과 라이선싱
제7장 주요 기업 개요
Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody
ksm
영문 목차
영문목차
Neoantigen Cancer Vaccine Trends and Forecast
The future of the global neoantigen cancer vaccine market looks promising with opportunities in the melanoma, brain cancer, gastrointestinal, and lung markets. The global neoantigen cancer vaccine market is expected to reach an estimated $90.3 million by 2030 with a CAGR of 22.4% from 2024 to 2030. The major drivers for this market are growing use of personalized medicine for customized patient care, rising incidence of cancer globally, and ongoing advancements in immunotherapy and personalized medicine.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Neoantigen Cancer Vaccine by Segment
The study includes a forecast for the global neoantigen cancer vaccine by product, route of administration, cell, application, and region.
Neoantigen Cancer Vaccine Market by Product [Shipment Analysis by Value from 2018 to 2030]:
Personalized Neo-Antigen Vaccine
Off-The Shell Neoantigen Vaccine
Neoantigen Cancer Vaccine Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:
Intravenous
Intramuscular
Transdermal
Others
Neoantigen Cancer Vaccine Market by Cell [Shipment Analysis by Value from 2018 to 2030]:
Autologous
Allogenic
Neoantigen Cancer Vaccine Market by Application [Shipment Analysis by Value from 2018 to 2030]:
Melanoma
Brain Cancer
Gastrointestinal
Lung
Others
Neoantigen Cancer Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:
North America
Europe
Asia Pacific
The Rest of the World
List of Neoantigen Cancer Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neoantigen cancer vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neoantigen cancer vaccine companies profiled in this report include-
Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody
Neoantigen Cancer Vaccine Market Insights
Lucintel forecasts that personalized neo-antigen is expected to witness higher growth over the forecast period.
Within this market, lung is expected to witness the highest growth over the forecast period.
North America is expected to witness the highest growth over the forecast period.
Features of the Global Neoantigen Cancer Vaccine Market
Market Size Estimates: Neoantigen cancer vaccine market size estimation in terms of value ($M).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Neoantigen cancer vaccine market size by various segments, such as by product, route of administration, cell, application, and region in terms of value ($M).
Regional Analysis: Neoantigen cancer vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different products, route of administrations, cells, applications, and regions for the neoantigen cancer vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neoantigen cancer vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the neoantigen cancer vaccine market size?
Answer: The global neoantigen cancer vaccine market is expected to reach an estimated $90.3 million by 2030.
Q2. What is the growth forecast for neoantigen cancer vaccine market?
Answer: The global neoantigen cancer vaccine market is expected to grow with a CAGR of 22.4% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the neoantigen cancer vaccine market?
Answer: The major drivers for this market are growing use of personalized medicine for customized patient care, rising incidence of cancer globally, and ongoing advancements in immunotherapy and personalized medicine.
Q4. What are the major segments for neoantigen cancer vaccine market?
Answer: The future of the neoantigen cancer vaccine market looks promising with opportunities in the melanoma, brain cancer, gastrointestinal, and lung markets.
Q5. Who are the key neoantigen cancer vaccine market companies?
Answer: Some of the key neoantigen cancer vaccine companies are as follows:
Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody
Q6. Which neoantigen cancer vaccine market segment will be the largest in future?
Answer: Lucintel forecasts that personalized neo-antigen is expected to witness higher growth over the forecast period.
Q7. In neoantigen cancer vaccine market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the neoantigen cancer vaccine market by product (personalized neo-antigen vaccine and off-the shell neoantigen vaccine), route of administration (intravenous, intramuscular, transdermal, and others), cell (autologous and allogenic), application (melanoma, brain cancer, gastrointestinal, lung, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Global Neoantigen Cancer Vaccine Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Neoantigen Cancer Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Neoantigen Cancer Vaccine Market by Product
3.3.1: Personalized Neo-Antigen Vaccine
3.3.2: Off-The Shell Neoantigen Vaccine
3.4: Global Neoantigen Cancer Vaccine Market by Route of Administration
3.4.1: Intravenous
3.4.2: Intramuscular
3.4.3: Transdermal
3.4.4: Others
3.5: Global Neoantigen Cancer Vaccine Market by Cell
3.5.1: Autologous
3.5.2: Allogenic
3.6: Global Neoantigen Cancer Vaccine Market by Application
3.6.1: Melanoma
3.6.2: Brain cancer
3.6.3: Gastrointestinal
3.6.4: Lung
3.6.5: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Neoantigen Cancer Vaccine Market by Region
4.2: North American Neoantigen Cancer Vaccine Market
4.2.1: North American Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
4.2.2: North American Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
4.3: European Neoantigen Cancer Vaccine Market
4.3.1: European Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
4.3.2: European Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
4.4: APAC Neoantigen Cancer Vaccine Market
4.4.1: APAC Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
4.4.2: APAC Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
4.5: ROW Neoantigen Cancer Vaccine Market
4.5.1: ROW Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
4.5.2: ROW Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Product
6.1.2: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Route of Administration
6.1.3: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Cell
6.1.4: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Application
6.1.5: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Region
6.2: Emerging Trends in the Global Neoantigen Cancer Vaccine Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Neoantigen Cancer Vaccine Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neoantigen Cancer Vaccine Market
